Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations

Autor: Rebecca Rochman, Kamran Majeed, Richard G. Jung, Young Jung, Robert Moreland, Benjamin Hibbert, Anne Claire Duchez, Trevor Simard, Pietro Di Santo, Pouya Motazedian, Alisha Labinaz
Rok vydání: 2019
Předmět:
Male
Target lesion
Coronary angiography
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism

medicine.medical_treatment
Clinical Decision-Making
Coronary Artery Disease
030204 cardiovascular system & hematology
Coronary Angiography
Risk Assessment
Coronary artery disease
03 medical and health sciences
chemistry.chemical_compound
Percutaneous Coronary Intervention
0302 clinical medicine
Predictive Value of Tests
Risk Factors
Internal medicine
Plasminogen Activator Inhibitor 1
Internal Medicine
medicine
Humans
In patient
Prospective Studies
Registries
Aged
030304 developmental biology
0303 health sciences
business.industry
Percutaneous coronary intervention
Middle Aged
Prognosis
medicine.disease
chemistry
Plasminogen activator inhibitor-1
Cardiology
Biomarker (medicine)
Female
Cardiology and Cardiovascular Medicine
business
Medical therapy
Biomarkers
Zdroj: Diabetes and Vascular Disease Research. 16:478-482
ISSN: 1752-8984
1479-1641
DOI: 10.1177/1479164119845123
Popis: Introduction and objective:Target lesion failure continues to limit the efficacy of percutaneous coronary intervention despite advancements in stent design and medical therapy. Identification of biomarkers to risk stratify patients after percutaneous coronary intervention has the potential to focus therapies on cohorts with increased benefits. Plasminogen activator inhibitor-1 has been identified as a candidate biomarker. Herein, we evaluate biological variables which impact plasminogen activator inhibitor-1 levels and analytical characteristics which impact its utility as a biomarker in humans.Methods:Plasma plasminogen activator inhibitor-1 was measured in 689 patients undergoing coronary angiography. Plasminogen activator inhibitor-1 levels were measured. Clinical and procedural characteristics were collected in a prospective registry.Results:Plasma plasminogen activator inhibitor-1 analytical ( CVa= 4.1%), intra-individual ( CVi= 44.0%) and inter-individual ( CVg= 118.6%) variations with reference change value of 122.3% were calculated. Plasminogen activator inhibitor-1 levels were elevated in patients with cardiovascular risk factors, including type 2 diabetes, pre-diabetes, smokers, obesity, hypertension, and daytime variation in procedure and blood draw.Conclusion:Variation in plasma plasminogen activator inhibitor-1 levels is influenced by multiple biological and procedural characteristics. The performance of plasma plasminogen activator inhibitor-1 is consistent with biomarkers in clinical use (N-terminal pro-B-type natriuretic peptide and C-reactive protein) and its applicability is promising.
Databáze: OpenAIRE